Depemokimab for COPD with type 2 inflammation
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new medicine, depemokimab, given as an injection to help reduce flare-ups (exacerbations) in adults with moderate to severe COPD who have a certain type of inflammation. The goal is to see if it can keep you healthier for longer with fewer serious breathing attacks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have moderate to severe COPD and have had at least 2 moderate or 1 severe flare-up in the last year.
- Your blood test shows high levels of eosinophils (a type of white blood cell linked to inflammation).
- You have smoked cigarettes for at least 10 pack-years (e.g., 1 pack a day for 10 years) and are a current or former smoker.
- You are already using a combination of three inhaled medicines (steroid + long-acting bronchodilators) for at least 6 months.
- You do not have asthma, other serious lung disease, or unstable heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This study tests a new medicine called depemokimab, given as an injection, to see if it can reduce asthma attacks in people with a specific type of asthma (type 2 high). If you have had asthma for several years and have had recent attacks despite using regular inhalers, this trial might be an option for you.
This study tests depemokimab, an injectable biologic, to see how it works in the lungs of people with severe asthma. You would get the drug and have special imaging and a bronchoscopy (a tube with a camera placed into your airways to take tiny tissue samples) so doctors can understand how the medicine reduces inflammation.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
Hear when a new Pulmonary Disease, Chronic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.